Evidence map›Paper›PMID 41667896›Full record

ArticleAnnals of hematology2026

Chronic lymphocytic leukemia with IGH/BCL2 fusion and clonal heterogeneity: phenotypic and molecular profiling analysis of a rare case.

Ting Zhang, Dan Liu, Fanggang Ren, Jian Hao, Feng Ye, Yakun Chen, Bianbian Qiao, Yaofang Zhang, Jianmei Chang, Hongwei Wang and 1 more

Abstract readCase Reports
In one paragraph

Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ting ZhangInstitute of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Dan LiuInstitute of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Fanggang RenInstitute of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Jian HaoInstitute of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Feng YeBeijing genomeprecision Medical Technology Co., Ltd, Beijing, China.
Yakun ChenBeijing genomeprecision Medical Technology Co., Ltd, Beijing, China.
Bianbian QiaoInstitute of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Yaofang ZhangInstitute of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Jianmei ChangInstitute of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Hongwei WangInstitute of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China. wanghw68@hotmail.com.
Zhifang XuInstitute of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China. xu_zfang@163.com.

Funding

Fund Program for the Scientific Activities of Selected Returned Overseas Professionals in Shanxi Province 20210027Research Project Plan of the Shanxi Provincial Health Commission 2021056
6 · The paper itself

Abstract

Clonal heterogeneity within chronic lymphocytic leukemia (CLL) has been increasingly recognized as a factor that may influence disease progression, treatment response, and prognosis. Here, we report a rare case of CLL with two distinct B-cell populations displaying distinct immunophenotypic characteristics, genetic mutations, and genetic evolution. The two aberrant mature B cell populations were identified in peripheral blood (PB) and bone marrow (BM) through multiparametric flow cytometry (MFC) with identical light chain restriction but distinct immunophenotypes. The first population (CD5 + CD23+CD200+) was consistent with typical CLL, while the second (CD5-CD23-CD200-) displayed atypical features. Further characterization through flow sorting, fluorescence in situ hybridization (FISH), and next-generation sequencing (NGS) revealed that both populations shared the same BCL2-IgH translocation and an identical IGHV gene usage, but exhibited different IGHV mutation rates. NGS revealed that a common progenitor cell with BCL2-IgH translocation and mutations in TP53, KMT2A, KMT2C, and KMT2D gave rise to two distinct subclones: one (CD5 + CD23+CD200+) CLL driven by mutations in TNFAIP3 and BCORL1, and the other (CD5-CD23-CD200-) driven by mutations in EP300, NOTCH1, and BCL2. This case highlights the significance of clonal heterogeneity in CLL and underscores the crucial role of MFC, flow sorting, and molecular genetics in diagnosing and understanding the complex evolution of this disease.

Indexed as

Immunoglobulin Heavy ChainsLeukemia, Lymphocytic, Chronic, B-CellOncogene Proteins, FusionProto-Oncogene Proteins c-bcl-2Flow CytometryHigh-Throughput Nucleotide SequencingHumansImmunophenotypingMaleMutationPhenotypeBCL2 protein, humanImmunoglobulin Heavy ChainsOncogene Proteins, FusionProto-Oncogene Proteins c-bcl-2Chronic lymphoid leukemia (CLL)Fluorescence activated cell sorting (FACS)Multiparametric flow cytometry (MFC)Next-Generation sequencing (NGS)

Identifiers

PMID41667896
PMCPMC12891074

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.